Related Experiment Video

Updated: Jan 17, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.3K

GKB7I-53: A novel anti-metastatic agent for colorectal cancer

Min Hee Yang1, Ducdat Le2, Thinhulinh Dang3

  • 1Department of Science in Korean Medicine, Kyung Hee University, 24 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea.

Toxicology and Applied Pharmacology
|January 14, 2026
PubMed

Insights

A novel saponin compound, GKB7I-53, effectively inhibits colorectal cancer metastasis by targeting epithelial-mesenchymal transition (EMT) pathways without significant cytotoxicity. Further studies are needed for therapeutic validation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Colorectal cancer metastasis driven by epithelial-mesenchymal transition (EMT) presents a significant therapeutic challenge.
  • Targeting EMT pathways offers a promising strategy for inhibiting cancer progression and spread.

Purpose of the Study:

  • To investigate the potential of GKB7I-53, a saponin compound, as an anti-metastatic agent targeting EMT in colorectal cancer.
  • To elucidate the molecular mechanisms underlying GKB7I-53's effects on EMT and metastasis.

Main Methods:

  • Feature-based molecular networking for compound isolation.
  • In vitro assays to assess cytotoxicity, cell migration, invasion, and MMP-2/9 activity.
  • Analysis of epithelial and mesenchymal marker expression.
  • Investigation of the JAK/STAT3 signaling pathway and MnSOD involvement.
  • Molecular docking studies.

Main Results:

  • GKB7I-53 exhibited minimal cytotoxicity and effectively suppressed EMT by downregulating mesenchymal markers (CXCR4, CXCR7) and upregulating epithelial markers (E-cadherin, occludin).
  • The compound significantly reduced cell migration and invasion, and inhibited MMP-2/9 activity in CXCL12-stimulated cells.
  • GKB7I-53 suppressed MnSOD-induced STAT3 activation, blocking the JAK/STAT3 pathway crucial for metastasis.
  • Molecular docking confirmed strong binding affinity to EMT-related target proteins.

Conclusions:

  • GKB7I-53 demonstrates potent anti-metastatic properties in colorectal cancer by selectively modulating EMT pathways.
  • The compound acts by inhibiting the JAK/STAT3 signaling pathway, offering a novel therapeutic approach.
  • GKB7I-53 shows promise as a lead compound for colorectal cancer treatment, warranting further in vivo and preclinical investigation.
Keywords:
EMTFBMNGKB7I-53MnSODMolecular DockingMolecular Simulation

More Related Videos

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

6.0K
Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer06:19

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

10.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
460
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
602
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.4K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
588